Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Gurusamy, Kurinchi Selvan ^a   Koti, Rahul ^a   Toon, Clare D ^b   Wilson, Peter ^c   Davidson, Brian R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b WEST SUSSEX COUNTY COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; DAPTOMYCIN; ERTAPENEM; MOXIFLOXACIN; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTIBIOTIC AGENT;

ADVERSE EVENT; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY RATE; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; WOUND INFECTION; DIABETIC FOOT; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS INFECTION; ALL CAUSE MORTALITY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; INTERVENTION STUDY; LENGTH OF STAY; WOUND; WOUND HEALING;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS;

EID: 84900761245     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010427.pub2     Document Type: Review

References (138)

1. Lipsky B, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 2005;55(2):240-5.
2. Lipsky B, Armstrong D, Citron D, Tice A, Morgenstern D, Abramson M. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005;366(9498):1695-703.
3. Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, et al. Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin-clavulanate in the treatment of diabetic foot infections: Results of the RELIEF study. Clinical Microbiology and Infection 2010;16(Supp 2):S449-50.
4. Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, et al. Efficacy of moxifloxacin in the treatment of diabetic foot infections: Results of the RELIEF study. Diabetologia 2010;53(Supp 1):S462-3.
5. Bucko A, Hunt B, Kidd S, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg bid with either cefuroxime 250 mg bid or cefadroxil 500 mg bid for the treatment of uncomplicated skin and skin-structure infections. Clinical Therapeutics 2002;24(7):1134-47.
6. Cenizal M, Skiest D, Luber S, Bedimo R, Davis P, Fox P, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2007;51(7):2628-30.
7. Chen A, Carroll K, Diener West M, Ross T, Ordun J, Goldstein M, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 2011;127(3):e573-80.
8. Chuang Y, Chang C, Aradhya S, Nagari B, Pai V, Dartois N, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. Journal of Microbiology, Immunology and Infection 2011;44(2):116-24.
9. Corey G, Wilcox M, Talbot G, Friedland H, Baculik T, Witherell G, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clinical Infectious Diseases 2010;51(6):641-50.
10. Covington P, Davenport J, Andrae D, O'Riordan W, Liverman L, McIntyre G, et al. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrobial Agents and Chemotherapy 2011;55(12):5790-7.
11. Craft J, Moriarty S, Clark K, Scott D, Degenhardt T, Still J, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clinical Infectious Diseases 2011;52(Supp 7):S520-6.
12. Daniel R. Comparison of the efficacy and safety of once-daily oral trovafloxacin and 3-times-daily amoxicillin/clavulanic acid for the treatment of complicated skin and soft-tissue infections. Drugs 1999;58(Supp 2):288-90.
13. Deville J, Adler S, Azimi P, Jantausch B, Morfin M, Beltran S, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatric Infectious Disease Journal 2003;22(9 Supp):S158-63.
14. Donati L, Periti P. Antibiotic treatment of burned patients: an Italian multicentre study. Intensive Care Medicine 1994;20(Supp 4):S30-4.
15. Donati L, Periti P, Andreassi A, Dioguardi D, Gliori A, Landi G, et al. Increased burn patient survival with once-a-day high dose teicoplanin and netilmicin. An Italian multicenter study. Journal of Chemotherapy 1998;10(1):47-57.
16. Dunbar L, Milata J, McClure T, Wasilewski M. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrobial Agents and Chemotherapy 2011;55(7):3476-84.
17. Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Annals of Emergency Medicine 2010;55(5):401-7.
18. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. Journal of Antimicrobial Chemotherapy 2008;62(Supp 1):i17-28.
19. Friedland H, O'Neal T, Biek D, Eckburg P, Rank D, Llorens L, et al. CANVAS 1 and 2: Analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2012;56(5):2231-6.
20. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents 2005;26(5):357-65.
21. Giordano P, Elston D, Akinlade B, Weber K, Notario G, Busman T, et al. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Current Medical Research and Opinion 2006;22(12):2419-28.
22. Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Gesser R. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clinical Infectious Diseases 2002;35(Supp 1):S119-25.
23. Graham D, Lucasti C, Malafaia O, Nichols R, Holtom P, Perez N, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Diseases 2002;34(11):1460-8.
24. Gyssens I, Dryden M, Kujath P, Nathwani D, Schaper N, Arvis P, et al. In vitro susceptibility and pathogen prevalence data in complicated skin and skin-structure infections: results of the RELIEF study. Clinical Microbiology and Infection 2009;15(Supp 4):S675-6.
25. Gyssens I, Dryden M, Kujath P, Nathwani D, Schaper N, Hampel B, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2011;66(11):2632-42.
26. Harkless L, Boghossian J, Pollak R, Caputo W, Dana A, Gray S, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surgical Infections 2005;6(1):27-40.
27. Huovinen S, Kotilainen P, Jarvinen H, Malanin K, Sarna S, Helander I, et al. Comparison of ciprofloxacin or trimethoprim therapy for venous leg ulcers: results of a pilot study. Journal of the American Academy of Dermatology 1994;31(2 (Part 1)):279-81.
28. Itani K, Weigelt J, Li J, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents 2005;26(6):442-8.
29. Itani K, Dryden M, Bhattacharyya H, Kunkel M, Baruch A, Weigelt J. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. American Journal of Surgery 2010;199(6):804-16.
30. Jauregui L, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clinical Infectious Diseases 2005;41(10):1407-15.
31. Kaplan S, Deville J, Yogev R, Morfin M, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal 2003;22(8):677-86.
32. Kidson A, Lilly H, Lowbury E. Flucloxacillin treatment of methicillin-'resistant' and sensitive staphylococcal infection. Journal of Antimicrobial Chemotherapy 1979;5(4):359-64.
33. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. Journal of Antimicrobial Chemotherapy 2007;60(6):1361-9.
34. Konychev A, Heep M, Moritz RKC, Kreuter A, Shulutko A, Fierlbeck G, et al. A comparative randomised clinical trial against semisynthetic penicillins and glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections in the elderly. Clinical Microbiology and Infection 2012;18:838-9.
35. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2009;53(7):2834-40.
36. Li J, Willke R, Rittenhouse B, Rybak M. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infections 2003;4(1):57-70.
37. Lin D, Zhang Y, Wu J, Wang F, Zheng J, Miao J, et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. International Journal of Antimicrobial Agents 2008;32(3):241-9.
38. Lipsky B, Miller B, Schwartz R. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. Clinical Therapeutics 1999;21(4):675-90.
39. Liu J, Zhang Q, Liao Z. Efficacy and safety of teicoplanin in the treatment of Gram-positive bacterial infections in burns patients. Chinese Journal of Antibiotics 2005;30(10):617-21.
40. Lowbury E, Lilly H, Kidson A. "Methicillin-resistant" Staphylococcus aureus: reassessment by controlled trial in burns unit. British Medical Journal 1977;1(6068):1054-6.
41. Luke D, Reisman A, Capitano B, Huang D. Efficacy and safety of linezolid compared with vancomycin for treatment of methicillin-resistant Staphylococcus aureus complicated skin and skin structure infections in patients from long-term care facilities. Clinical Microbiology and Infection 2010;16(Supp S2):S712.
42. Manaktala C, Singh A, Verma M, Sachdeva A, Sharma H, Roy A, et al. Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients. Indian Journal of Dermatology 2009;54(4):350-6.
43. Markowitz N, Quinn E, Saravolatz L. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Annals of Internal Medicine 1992;117(5):390-8.
44. Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, et al. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. BMC Infectious Diseases 2012;12:297.
45. McCollum M, Sorensen S, Liu L. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics 2007;29(3):469-77.
46. McGovern P, Rill D, Zito E, Babinchak T. Efficacy of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate to treat complicated skin and skin structure infections-study 900. Clinical Microbiology and Infection 2010;16(Supp 2):S448.
47. McKinnon P, Sorensen S, Liu L, Itani K. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Annals of Pharmacotherapy 2006;40(6):1017-23.
48. Miller L, Mooney C, Hansbrough J. Comparative evaluation of cefaclor versus cefadroxil in the treatment of skin and skin structure infections. Current Therapeutic Research 1989;46(Sep):405-10.
49. Nichols R, Graham D, Barriere S, Rodgers A, Wilson S, Zervos M, et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Journal of Antimicrobial Chemotherapy 1999;44(2):263-73.
50. Noel G, Strauss R, Amsler K, Heep M, Pypstra R, Solomkin J. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrobial Agents and Chemotherapy 2008;52(1):37-44.
51. Noel G, Draper M, Hait H, Tanaka S. Safety and efficacy of PTK 0796 (omadacycline) as treatment of complicated skin and soft tissue infection. Clinical Microbiology and Infection 2012;18:123-4.
52. Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2012;56(11):5650-4.
53. O'Riordan W, Surber J, Manos P, Mehra P, Babazadeh S, Hopkins S, et al. Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections. Clinical Microbiology and Infection 2009;15(Supp S4):S519.
54. Olderog C, Schmitz G, Pitotti R, Williams J, Huebner K, Livengood T, et al. Double-blind, randomized, controlled multi-center trial of antibiotic treatment for uncomplicated skin abscesses in patients at risk for community-acquired methicillin-resistant staphylococcus aureus infection: an interim analysis. Annals of Emergency Medicine 2009;54(3 Supp):S105.
55. Pakrooh H. A comparison of sodium fusidate ointment ('Fucidin') alone versus oral antibiotic therapy in soft-tissue infections. Current Medical Research and Opinion 1977;5(4):289-94.
56. Parish L, Witkowski J, Snow R, Eron L, Mogabgab W. Cephalosporins in cutaneous infections A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections. International Journal of Dermatology 1986;25(4):258-65.
57. Postier R, Green S, Klein S, Ellis Grosse E, Loh E, Tigecycline 200SG. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clinical Therapeutics 2004;26(5):704-14.
58. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2011;55(2):583-92.
59. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309(6):559-69.
60. Rajendran P, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrobial Agents and Chemotherapy 2007;51(11):4044-8.
61. Ralph Corey G, Wilcox M, Talbot G, Thye D, Friedland D, Baculik T. CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2010;65(Supp 4):iv41-51.
62. Ramirez Ronda C, Saavedra S, Rivera-Vazquez C. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. American Journal of Medicine 1987;82(4A):220-3.
63. Schmitz G, Pitotti R, Olderog C, Livengood T, Williams J. Prospective randomized trial of trimethoprim-sulfamethoxazole vs placebo on 30-day recurrence rates for uncomplicated skin abscesses in patients at risk for community-acquired methicillin-resistant staphylococcus aureus infection: an interim analysis. Annals of Emergency Medicine 2009;54(3 Supp):S104.
64. Schmitz G, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Annals of Emergency Medicine 2010;56(3):283-7.
65. Schrenzel J, Harbarth S, Schockmel G, Genne D, Bregenzer T, Flueckiger U, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.[see comment]. Clinical Infectious Diseases 2004;39(9):1285-92.
66. Sharpe J, Shively E, Polk HJ. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. American Journal of Surgery 2005;189(4):425-8.
67. Siami G, Christou N, Eiseman I, Tack K, Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2001;45(2):525-31.
68. Siami F, LaFleur B, Siami G. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs Medical Center. Clinical Therapeutics 2002;24(1):59-72.
69. Sinha R, Agarwal R, Agarwal M. Povidone iodine plus neosporin in superficial burns - a continuing study. Burns 1997;23(7-8):626-8.
70. Smith S, Eng R, Tecson Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrobial Agents and Chemotherapy 1989;33(2):181-4.
71. Stevens D, Herr D, Lampiris H, Hunt J, Batts D, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 2002;34(11):1481-90.
72. Stryjewski M, O'Riordan W, Lau W, Pien F, Dunbar L, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clinical Infectious Diseases 2005;40(11):1601-7.
73. Stryjewski M, Chu V, O'Riordan W, Warren B, Dunbar L, Young D, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrobial Agents and Chemotherapy 2006;50(3):862-7.
74. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, et al. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2012;56(11):5476-83.
75. Talbot G, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2007;51(10):3612-6.
76. Tan J, Wishnow R, Talan D, Duncanson F, Norden C. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrobial Agents and Chemotherapy 1993;37(8):1580-6.
77. Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. American Journal of Medicine 1993;94(3A):159S-65S.
78. Valtonen V, Karppinen L, Kariniemi A. A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. Scandinavian Journal of Infectious Diseases Supplement 1989;60:79-83.
79. Vick-Fragoso R, Hernandez-Oliva G, Cruz-Alcazar J, Amabile-Cuevas C, Arvis P, Reimnitz P, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009;37(5):407-17.
80. Wacha H, Forster H. Comparison of quinupristin/dalfopristin with standard therapies for the treatment of complicated skin and soft tissue infections due to gram-positive pathogens: Results of two open, randomized multicenter studies. Chemotherapie Journal Supplement 2000;9(19):63-8.
81. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2005;49(6):2260-6.
82. Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatric Infectious Disease Journal 2003;22(4):315-23.
83. Wilcox M, Ralph Corey G, Talbot G, Thye D, Friedland D, Baculik T. CANVAS 2: The second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 2010;65(Supp 4):iv53-65.
84. Wilson S, O'Riordan W, Hopkins A, Friedland H, Barriere S, Kitt M, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. American Journal of Surgery 2009;197(6):791-6.
85. Golcman B, Tuma S, Golcman R, Schalka S, Gonzalez M. Efficacy and safety of cefprozil and cefaclor on cutaneous infections. Anais Brasileiros de Dermatologia 1997;72(1):79-82.
86. Bang RL, Sharma PN, Sanyal SC, Bang S, Ebrahim MK. Burn septicaemia in Kuwait: associated demographic and clinical factors. Medical Principles and Practice 2004;13(3):136-41.
87. Barber M. Methicillin-resistant staphylococci. Journal of Clinical Pathology 1961;14:385-93.
88. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Current Medical Research and Opinion 2010;26(2):407-21.
89. Boyce JM, Jackson MM, Pugliese G, Batt MD, Fleming D, Garner JS, et al. Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infection Control and Hospital Epidemiology 1994;15(2):105-15.
90. Cataldo MC, Caputo G, Calabrese A, Nicolicchia M, Rizzo G, Mammina C. Methicillin-resistant Staphylococcus aureus from pressure ulcers in patients receiving home care in Palermo, Italy. Scandinavian Journal of Infectious Diseases 2010;42(2):158-9.
91. Deeks JJ, Higgins JPT, Altman DG (editors), on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
92. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
93. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
94. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ Journal of Surgery 2009;79(9):629-35.
95. Dumville JC, Worthy G, Soares MO, Bland JM, Cullum N, Dowson C, et al. VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers. Health Technology Assessment 2009;13(55):1-182.
96. ECDC. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. http://www.ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf 2009 (accessed on 17 July 2011).
97. ECDC. European Centre for Disease Prevention and Control. The bacterial challenge: time to react. A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of new anti-bacterial agents. http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf 2009 (accessed on 17 July 2011).
98. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
99. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2003;47(1):196-203.
100. Ganesamoni S, Kate V, Sadasivan J. Epidemiology of hospitalized burn patients in a tertiary care hospital in South India. Burns 2010;36(3):422-9.
101. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. British Journal of Surgery 2009;96(4):342-9.
102. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
103. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
104. Higgins JPT, Altman DG, Sterne JAC (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
105. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Higgins JPT, Deeks JJ, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
107. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1996.
108. Jevons PM. “Celbenin” - resistant staphylococci. British Medical Journal 1961;1(5219):124-5.
109. Kaiser ML, Thompson DJ, Malinoski D, Lane C, Cinat ME. Epidemiology and risk factors for hospital-acquired methicillin-resistant Staphylococcus aureus among burn patients. Journal of Burn Care and Research 2011;32(3):429-34.
110. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010;304(6):641-8.
111. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clinical Infectious Diseases 2008;46(10):1568-77.
112. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
113. Klimek JJ, Marsik FJ, Bartlett RC, Weir B, Shea P, Quintiliani R. Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital. American Journal of Medicine 1976;61(3):340-5.
114. Knox R, Smith JT. The nature of penicillin resistance in staphylococci. Lancet 1961;2(7201):520-2.
115. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerging Infectious Diseases 2005;11(6):http://www.cdc.gov/ncidod/EID/vol11no06/4-0831.htm.
116. Lamagni TL, Potz N, Powell D, Pebody R, Wilson J, Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004-2005. Journal of Hospital Infection 2011;77(1):16-20.
117. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
118. Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. International Journal of Infectious Diseases 2011;15(2):e131-5.
119. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases 2011;52(3):285-92.
120. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. The Journal of Antimicrobial Chemotherapy 2003;52(3):331-44.
121. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
122. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
123. Murray CK, Roop SA, Hospenthal DR, Dooley DP, Wenner K, Hammock J, et al. Bacteriology of war wounds at the time of injury. Military Medicine 2006;171(9):826-9.
124. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
125. O'Toole RD, Drew WL, Dahlgren BJ, Beaty HN. An outbreak of methicillin-resistant Staphylococcus aureus infection. Observations in hospital and nursing home. JAMA 1970;213(2):257-63.
126. OED. Oxford English Dictionary. The definitive record of the English language. http://www.oed.com/2011 (accessed on 7 April 2011).
127. Otter JA, French GL. Community-associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection. Journal of Hospital Infection 2011;14(7):670-6.
128. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
129. Pirett CCNS, Braga IO, Ribas RM, Filho PPG, Filho AD. Pressure ulcers colonized by MRSA as a reservoir and risk for MRSA bacteremia in patients at a Brazilian University Hospital. Wounds 2012;24(2):64-75.
130. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
131. Roghmann MC, Siddiqui A, Plaisance K, Standiford H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. Journal of Hospital Infection 2001;47(2):98-103.
132. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
133. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (editors) on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
134. Scottish Intercollegiate Guidelines Network. Search filters. http://www.sign.ac.uk/methodology/filters.html (accessed 2 September 2011).
135. Skov R, SSAC MRSA Working Party. MRSA infections increasing in the Nordic countries. Euro Surveillance 2005;10(31):E050804.2.
136. Wang JT, Wang JL, Fang CT, Chie WC, Lai MS, Lauderdale TL, et al. Risk factors for mortality of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community-associated MRSA strains. Journal of Infection 2010;61(6):449-57.
137. Wibbenmeyer L, Williams I, Ward M, Xiao X, Light T, Latenser B, et al. Risk factors for acquiring vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus on a burn surgery step-down unit. Journal of Burn Care and Research 2010;31(2):269-79.
138. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.